Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
House panel hears heated debate over 340B changes as employers and hospitals clash
Summary
Witnesses at the House Insurance Committee hearing on HB 276 clashed over proposed changes to the 340B drug-pricing program: pharmaceutical industry representatives warned state mandates will worsen costs, while hospitals and employer groups called for transparency and protections to ensure savings reach patients.
The House Insurance Committee heard more than two hours of testimony and questions on House Bill 276 on Wednesday as industry groups, hospitals and employer coalitions delivered sharply divergent views of the 340B drug-pricing program.
Kip Snyder, state policy lead for the Pharmaceutical Research and Manufacturers of America, told the committee the program has outgrown its original purpose. "It's now a $66,000,000,000 program, which makes it second only to the Medicare part D program," Snyder said, arguing rapid growth in contract pharmacy arrangements has enabled exploitation and could drive up costs if states expand the program. He said nationwide contract pharmacy arrangements rose from about 2,300 in 2010 to roughly 205,000 today and that Ohio has about…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
